Compugen Ltd. (CGEN)
NASDAQ: CGEN · IEX Real-Time Price · USD
2.160
+0.170 (8.54%)
At close: May 2, 2024, 4:00 PM
2.190
+0.030 (1.39%)
After-hours: May 2, 2024, 7:25 PM EDT
Compugen Revenue
In the year 2023, Compugen had annual revenue of $33.46M with 346.12% growth. Revenue in the quarter ending December 31, 2023 was $33.46M.
Revenue (ttm)
$33.46M
Revenue Growth
+346.12%
P/S Ratio
5.78
Revenue / Employee
$492,044
Employees
68
Market Cap
193.39M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 17.80M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 712.00K | -8.57M | -92.33% |
Dec 31, 2015 | 9.28M | -3.09M | -24.99% |
Dec 31, 2014 | 12.37M | 8.82M | 248.46% |
Dec 31, 2013 | 3.55M | 3.31M | 1,366.53% |
Dec 31, 2012 | 242.00K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 1.12M | 865.00K | 346.00% |
Dec 31, 2009 | 250.00K | -88.00K | -26.04% |
Dec 31, 2008 | 338.00K | 158.00K | 87.78% |
Dec 31, 2007 | 180.00K | -35.00K | -16.28% |
Dec 31, 2006 | 215.00K | -431.00K | -66.72% |
Dec 31, 2005 | 646.00K | -1.98M | -75.44% |
Dec 31, 2004 | 2.63M | -4.15M | -61.19% |
Dec 31, 2003 | 6.78M | -4.32M | -38.94% |
Dec 31, 2002 | 11.10M | -263.00K | -2.32% |
Dec 31, 2001 | 11.36M | 4.00M | 54.41% |
Dec 31, 2000 | 7.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
P3 Health Partners | 1.27B |
High Tide | 497.66M |
The Joint | 117.70M |
Semler Scientific | 68.18M |
Genfit | 42.42M |
bluebird bio | 21.73M |
MediWound | 18.69M |
CGEN News
- 7 days ago - Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 - PRNewsWire
- 22 days ago - Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 - PRNewsWire
- 4 weeks ago - Compugen to Participate in Two Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy - PRNewsWire
- 2 months ago - Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 - PRNewsWire
- 2 months ago - Compugen Reports Fourth Quarter and Full Year 2023 Results - PRNewsWire
- 2 months ago - Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 - PRNewsWire
- 2 months ago - Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 - PRNewsWire